IOVA
Iovance Biotherapeutics, Inc.
$3.93
-0.11 (-2.72%)
At close · Jul 14
Market Cap
$1.71B
Shares
446,502,396
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$263.5M
+60.6%
FY2025
Net Income
-$390.98M
-5.1%
FY2025
Gross Margin
34.28%
+9.8pp
FY2025
Operating Margin
-153.08%
+87.8pp
FY2025
Diluted EPS
-$1.09
+14.8%
FY2025
Operating Cash Flow
-$302.41M
+14.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $350M – $370M | $285.61M | $263.5M | $164.07M | $1.19M | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | |
| — | $630K | — | — | — | — | — | — | — | — | — | — | $200K | — | -$2.52M | — | — | |
| — | $172.97M | $173.18M | $124M | $10.76M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $112.64M | $90.32M | $40.08M | -$9.57M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 34.28% | 24.43% | -804.54% | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $286.79M | $300.27M | $282.34M | $344.08M | $294.78M | $259.04M | $201.73M | $166.02M | $99.83M | $71.62M | $28.04M | $15.47M | $2.7M | $4.91M | $3.58M | $1.93M | |
| — | $147.47M | $152.32M | $153.02M | $106.92M | $104.1M | $83.66M | $60.21M | $40.85M | $28.43M | $21.26M | $25.6M | $12.39M | — | — | — | — | |
| — | $23.3M | $23.08M | $21.2M | $9.85M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $13.12M | $12.86M | $11.97M | $11.57M | $9.31M | $3.11M | $1.14M | $1.17M | $956K | $952K | $978K | $999K | $88.22K | $77.37K | $70.29K | $64.08K | |
| — | — | $5.14M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $418.02M | — | — | — | $398.88M | $342.7M | $261.94M | $206.87M | $128.26M | $92.88M | $53.64M | $27.86M | $12.04M | $52.88M | $30.24M | $22.11M | |
| — | $648.79M | $666.86M | $559.35M | $461.75M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$363.18M | -$403.36M | -$395.28M | -$460.56M | -$398.88M | -$342.7M | -$261.94M | -$206.87M | -$128.26M | -$92.88M | -$53.64M | -$27.86M | -$12.04M | -$52.88M | -$30.24M | -$22.11M | |
| — | — | -153.08% | -240.92% | -38734.99% | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$350.06M | -$390.49M | -$383.31M | -$448.99M | -$389.57M | -$339.59M | -$260.8M | -$205.7M | -$127.3M | -$91.93M | -$52.66M | -$26.86M | -$11.95M | -$52.8M | -$30.17M | -$22.04M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$5660 | — | $2.07M | $151.51K | |
| — | $8.42M | $10.31M | $20.27M | $13.04M | $2.99M | $451K | $2.36M | $9.32M | $4.68M | $813K | $745K | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $200K | $5660 | -$3.18M | -$443.08K | -$5.27M | |
| — | -$354.76M | -$393.05M | -$375.01M | -$447.52M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$898K | -$2.07M | -$2.83M | -$3.48M | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| — | -$353.86M | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -$342.25M | -$259.58M | -$197.56M | -$123.58M | -$92.06M | -$52.89M | -$27.66M | -$12.03M | -$56.07M | -$30.68M | -$27.38M | |
| — | — | -148.38% | -226.84% | -37345.42% | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$123.58M | -$92.06M | -$102.35M | -$27.66M | -$12.03M | -$64.53M | — | — | |
| — | -$347.5M | -$373.49M | -$375.75M | -$440.61M | -$396.19M | -$342.87M | -$259.78M | -$197.29M | -$123.62M | -$92.09M | -$52.91M | -$27.61M | — | — | — | — | |
| USD/shares | — | — | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 357.35K | 289.88K | 235.13K | 159.26K | 153.41K | 138.3K | 124.34K | 97.28K | 65.24K | 55.27K | 44.41M | 24.99M | 9.76M | 79.85M | — |
| shares | — | — | 357.35K | 289.88K | 235.13K | 159.26K | 153.41K | 138.3K | 124.34K | 97.28K | 65.24K | 55.27K | 44.41M | 24.99M | 9.76M | 79.85M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.25×
EV/EBIT
—
Biotechnology median 25.48×
P/E (TTM)
—
Biotechnology median 7.40×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Single Reportable Segment | $263,502,000 | $164,070,000 | $1,189,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| United States | $259,013,000 | $161,043,000 | — |
| Non Us | $4,489,000 | $3,027,000 | $1,189,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Amtagvi | $220,024,000 | $103,567,000 | — |
| Proleukin | $43,478,000 | $60,503,000 | $1,189,000 |
Key facts
CIK
1425205
CUSIP
462260100
13F (30d)
11 filings
10 filers
Visit website
Investor relations